Community Pharm PCL


Community Pharm PCL
Concise Prescribing Info
Ciprofloxacin HCl
Acute sinusitis & uncomplicated cystitis (in women), bone & joint infections, chronic bacterial prostatitis, complicated intra-abdominal infections, infectious diarrhea, low resp tract infections, skin & skin structure infections, typhoid fever (enteric fever), uncomplicated cervical & urethral gonorrhea, UTI, complicated UTI & pyelonephritis, inhalational anthrax (postexposure).
Dosage/Direction for Use
Adult Acute sinusitis Mild/moderate: 500 mg bid for 10 days. Bone & joint infections Mild/moderate: 500 mg bid for ≥4 to 6 wk. Severe/complicated: 750 mg bid for ≥4 to 6 wk. Chronic bacterial prostatitis Mild/moderate: 500 mg bid for 28 days. Infectious diarrhea Mild/moderate/severe: 500 mg bid for 5-7 days. Inhalation anthrax (postexposure) 500 mg bid for 60 days. Intra-abdominal infections Complicated: 500 mg bid for 7-14 days. Lower resp tract, skin & skin structure  infections Mild/moderate: 500 mg bid for 7-14 days. Severe/complicated: 750 mg bid for 7-14 days. Typhoid fever Mild/moderate: 500 mg bid for 10 days. Urethral & cervical gonococcal infections Uncomplicated: 250 mg single dose. UTI Acute, uncomplicated: 250 mg bid for 3 days. Mild/moderate: 250 mg bid 7-14 days. Severe/complicated: 500 mg bid 7-14 days. Childn Complicated UTI or pyelonephritis 10-20 mg/kg bid for 10-21 days. Max: 750 mg/dose even in patients weighing >51 kg. Inhalation anthrax (postexposure) 15 mg/kg bid for 60 days. Max: 500 mg/dose.
May be taken with or without food: Take 2 hr before or after dairy products (eg, milk) or Ca-fortified products (eg, juices).
Hypersensitivity to ciprofloxacin or other quinolones. Patients receiving tizanidine.
Special Precautions
May increase risk of tendinitis or tendon rupture; discontinue if pain, swelling, inflammation or rupture of tendon occurs. Patients w/ known or suspected CNS disorder that predispose to seizures or lower the seizure threshold. Concomitant use w/ drugs metabolized by CYP450 isoenzyme IA2 eg, theophylline, methylxanthines, tizanidine. Avoid excessive exposure to sunlight or artificial UV light. Discontinue if phototoxicity occurs. Patients receiving drug that can prolong QT interval (eg, class IA or III antiarrhythmic agents) or those w/ risk factors for Torsades de pointes (eg, known QT prolongation, uncorrected hypokalemia).
Adverse Reactions
Restlessness. Arrhythmia, cardiac murmur, CV collapse, hypotension, tachycardia; anxiety, depersonalization, dysphasia, lightheadedness, manic reaction, paranoia, phobia, toxic psychosis, unresponsiveness, weakness; anorexia, C. difficile-associated diarrhea, hepatic necrosis, ileus, jaundice, oral ulceration, pancreatitis; albuminuria, candiduria, crystalluria, cylindruria, frequent urination, gynecomastia, hematuria, hemorrhagic cystitis, renal calculi; achiness, arthralgia, flare-up of gout, jaw, arm or back pain, joint stiffness, neck & chest pain; pleural effusion, resp arrest, resp distress; erythema, inj site burning, pain, paresthesia, pruritus, swelling, thrombophlebitis.
Drug Interactions
Decreased absorption w/ antacids containing Mg, Al or Ca-containing drugs. May prolong QT interval w/ class IA or III antiarrhythmics. May increase risk of severe tendon disorders w/ corticosteroids. May shorten time to peak plasma conc w/ metoclopramide. May increase risk of CNS stimulation w/ NSAIDs. Interfere renal tubular secretion w/ probenecid. May increase serum conc & AUC of tizanidine. May increase & prolong serum conc of theophylline.
MIMS Class
ATC Classification
J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Pharproxin film-coated tab 250 mg
10 × 10's
Pharproxin film-coated tab 500 mg
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in